Supreme Court Attacks Dept. Of Labor Actions In Sales Rep Overtime Case
Executive Summary
The high court questioned the nature of pharmaceutical sales rep work and what constitutes a sale in the case Christopher v. SmithKline Beecham; Justice Stephen Breyer asked GSK’s attorney what the court should say in crafting an opinion.
You may also be interested in...
Sales Reps Overtime Suit Goes To Supreme Court; Could The IMS Win Bite Pharma?
The high court will hear oral arguments on whether sales reps sell drugs or just promote them; Thomas Goldstein, who won a victory for PhRMA in Sorrell v. IMS, is representing the sales reps and former Solicitor General Paul Clement is arguing for GlaxoSmithKline.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.